July 2026– date –
-
FDA Approves Multiple Novel Oncology Drugs in June 2026, Including ADC for Breast Cancer and Combination for Prostate Cancer
Targeted Oncology USA Overview In June 2026, the U.S. FDA granted several new drug approvals and expanded indications in oncology, notably for Gilead Sciences' antibody-drug conjugate (ADC), sacituzumab govitecan-hziy (Trodelvy), in two ... -
Light-Triggered Chitosan-Coated PLGA Nanoparticles Enable On-Demand Dexamethasone Delivery for Posterior Eye Disease
ACS Omega USA Overview A novel drug delivery system utilizing chitosan-coated PLGA nanoparticles, responsive to near-infrared (NIR) light, has been developed for the sustained and on-demand delivery of dexamethasone to treat posterior ey... -
Pharma’s AI Boom Misplaces Bottleneck Focus: Clinical Development Remains Key Challenge
ProMarket USA Overview The pharmaceutical industry's significant investment in AI drug discovery is reportedly misdirected, focusing heavily on early-stage efficiency while the critical bottlenecks persist in late-stage clinical developm... -
AI Accelerates Early Drug Discovery, But Patient Outcomes Remain the Ultimate Validation
MedCity News USA Overview Artificial intelligence is proving highly effective in accelerating early-stage drug discovery, with AI-designed candidates showing promising success rates in Phase 1 clinical trials. However, the ultimate value... -
COVID-19 mRNA Vaccines Comprehensively Proven Safe and Effective, Establishing Foundation for Future mRNA Therapeutics
CIDRAP (Center for Infectious Disease Research and Policy) USA Overview Extensive real-world use and rigorous evaluation of COVID-19 mRNA vaccines have conclusively demonstrated their comprehensive safety and efficacy, establishing a rob... -
The Rise of Oral GLP-1 Receptor Agonists: Transforming Diabetes and Obesity Treatment Convenience from Injections to Pills
Pharmacy Times USA Overview The advent of oral GLP-1 receptor agonists (GLP-1RAs) is fundamentally transforming drug administration in diabetes and obesity treatment. Oral formulations are rapidly gaining traction in the previously injec... -
Lonza Significantly Boosts ADC Manufacturing Capacity at Swiss Visp Site, Expanding Payload-Linker Production and Launching New Commercial Facility by 2028
Fierce Pharma Switzerland Overview Lonza announced a significant expansion of its ADC manufacturing capacity, extending a partnership with a major US drugmaker to meet the growing demand in the antibody-drug conjugate market. At its Visp... -
92Bio Doses First Patient in Phase 1 Trial of FOLR1×CD3 Bispecific T-Cell Engager NTB-928 for Platinum-Resistant Ovarian Cancer
BioPharm International USA Overview 92Bio has dosed the first patient in its Phase 1 clinical trial of NTB-928, a FOLR1×CD3 bispecific T-cell engager for platinum-resistant ovarian cancer. NTB-928 is designed to specifically kill ovarian... -
GLP-1 Receptor Agonists Expand Therapeutic Scope to MASH: Novo Nordisk’s Wegovy First FDA-Approved for MASH, Eli Lilly’s Oral Foundayo Launched
Drug Discovery Trends USA Overview The therapeutic scope of GLP-1 receptor agonists has expanded beyond diabetes and obesity to include cardiovascular risk, obstructive sleep apnea, chronic kidney disease, and by 2025, MASH (Metabolic Dy... -
FDA Approves, Clears Trials for Autism-Related Symptom Treatments: DeFloria’s AJA001 Oral Liquid Enters Phase 2, Generic Leucovorin Approved
Barchart.com (via DelveInsight) USA Overview The FDA has authorized Phase II clinical trials for DeFloria's AJA001 oral liquid, a plant-derived drug candidate for autism spectrum disorder (ASD)-related symptoms. Additionally, in March 20...
